Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Federal Trade Commission
Citi
Fuji
Cerilliant
Mallinckrodt
QuintilesIMS
US Army
McKesson

Generated: November 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020866

« Back to Dashboard

NDA 020866 describes CYCLOSET, which is a drug marketed by Veroscience and is included in one NDA. It is available from one supplier. There are thirteen patents protecting this drug. Additional details are available on the CYCLOSET profile page.

The generic ingredient in CYCLOSET is bromocriptine mesylate. There are nine drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the bromocriptine mesylate profile page.
Summary for 020866
Tradename:CYCLOSET
Applicant:Veroscience
Ingredient:bromocriptine mesylate
Patents:13
Formulation / Manufacturing:see details
Pharmacology for NDA: 020866
Ingredient-typeErgolines
Medical Subject Heading (MeSH) Categories for 020866
Suppliers and Packaging for NDA: 020866
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CYCLOSET bromocriptine mesylate TABLET;ORAL 020866 NDA Santarus, Inc. 68012-258 68012-258-20 200 TABLET in 1 BOTTLE (68012-258-20)
CYCLOSET bromocriptine mesylate TABLET;ORAL 020866 NDA Santarus, Inc. 68012-258 68012-258-21 21 TABLET in 1 BOTTLE (68012-258-21)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 0.8MG BASE
Approval Date:May 5, 2009TE:RLD:Yes
Patent:➤ Sign UpPatent Expiration:Jul 25, 2023Product Flag?Substance Flag?Delist Request?
Patented Use:IMPROVEMENTS OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS
Patent:➤ Sign UpPatent Expiration:Jul 25, 2023Product Flag?Substance Flag?Delist Request?
Patented Use:IMPROVEMENTS OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS
Patent:➤ Sign UpPatent Expiration:Jul 25, 2023Product Flag?Substance Flag?Delist Request?
Patented Use:IMPROVEMENTS OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS

Expired US Patents for NDA 020866

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 ➤ Sign Up ➤ Sign Up
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 ➤ Sign Up ➤ Sign Up
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 ➤ Sign Up ➤ Sign Up
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 ➤ Sign Up ➤ Sign Up
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Covington
QuintilesIMS
Cantor Fitzgerald
Moodys
Chinese Patent Office
Medtronic
Federal Trade Commission
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.